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Abstract: A recently proposed paradigm suggests that, like their dietary counterparts, digestion
of gastrointestinal endogenous proteins (GEP) may also produce bioactive peptides. With an aim
to test this hypothesis, in vitro digests of four GEP namely; trypsin (TRYP), lysozyme (LYS), mucin
(MUC), serum albumin (SA) and a dietary protein chicken albumin (CA) were screened for their
angiotensin-I converting (ACE-I), renin, platelet-activating factor-acetylhydrolase (PAF-AH) and
dipeptidyl peptidase-IV inhibitory (DPP-IV) and antioxidant potential following simulated in vitro
gastrointestinal digestion. Further, the resultant small intestinal digests were enriched to obtain
peptides between 3–10 kDa in size. All in vitro digests of the four GEP were found to inhibit ACE-I
compared to the positive control captopril when assayed at a concentration of 1 mg/mL, while
the LYS < 3-kDa permeate fraction inhibited renin by 40% (˘1.79%). The LYS < 10-kDa fraction
inhibited PAF-AH by 39% (˘4.34%), and the SA < 3-kDa fraction inhibited DPP-IV by 45% (˘1.24%).
The MUC < 3-kDa fraction had an ABTS-inhibition antioxidant activity of 150 (˘24.79) µM trolox
equivalent and the LYS < 10-kDa fraction inhibited 2,2-Diphenyl-1-picrylhydrazyl (DPPH) by 54%
(˘1.62%). Moreover, over 190 peptide-sequences were identified from the bioactive GEP fractions.
The findings of the present study indicate that GEP are a significant source of bioactive peptides
which may influence gut function.
Keywords: gut non-dietary proteins; lysozyme; serum albumin; angiotensin-I converting enzyme
(ACE-I) inhibition; renin inhibition; dipeptidyl peptidase IV inhibition; antioxidant peptides
1. Introduction
Gastrointestinal endogenous proteins (GEP) have been proposed [1,2] and recently identified
as a potential source of bioactive peptides based on in silico analysis [3]. GEP are made up of
gastrointestinal tract (GIT) epithelial turnover and gut microflora proteins [4] as well as soluble
secreted proteins. These include the human mucins, digestive enzymes, and serum albumin [4]. Other
contributors to GEP include the digestive hormones, immunoglobulins, lysozyme, and other gastric
and intestinal peptides [5]. Previous in silico experiments [3] identified 25 GEP as potential sources
of bioactive peptides possessing a range of biological activities. The aim of the present study was
to investigate if the GEP trypsin (P00761 (TRYP)), human lysozyme (P61626 (LYS)), salivary mucin
(P12021 (MUC)), human serum albumin (P02768 (SA)) and the dietary protein chicken albumin (P01012
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(CA)) are precursor proteins for bioactive peptides which can be released following GI digestion. The
selected proteins were screened for in vitro angiotensin-I converting enzyme (ACE-I; EC 3.4.15.1),
renin (EC 3.4.23.15), platelet-activating factor-acetylhydrolase (PAF-AH; EC 3.1.1.47) and dipeptidyl
peptidase-IV (DPP-IV; EC 3.4.14.5) inhibitory activities and in vitro antioxidant activities using the
2,2’-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) and 2,2-diphenyl-1-picrylhydrazyl
(DPPH) inhibition assays. The selected proteins were digested using an in vitro gastrointestinal
digestion model developed previously as part of the EU COST INFOGEST network [6]. After sequential
in vitro gastric and small intestinal digestion, freeze-dried samples were assessed for their in vitro
enzyme inhibitory activities.
Inhibition of the enzymes ACE-I, renin, PAF-AH and DPP-IV is known to lower systemic and
local blood pressure, and assist in the alleviation of symptoms of several disorders including diabetes
mellitus [7], hypercholesterolaemia, inflammatory diseases [8,9], and fibrosis [10]. Inhibition of ACE-I
prevents the formation of angiotensin II, a potent vasoconstrictor while renin inhibition prevents the
formation of angiotensin I, the precursor of angiotensin II [11]. It is now known that the GIT also
contains a local renin angiotensin aldosterone system (RAAS) [12], which plays a role in intestinal
fluid and electrolyte balance, and intestinal ischaemia [13]. PAF-AH catalyzes platelet-activating factor
(PAF), a pro-inflammatory phospholipid mediator that is involved in various inflammatory diseases
of the GIT [14], and elevated levels of PAF-AH are believed to be a risk factor for coronary heart
disease [15] and systemic inflammation [16,17]. DPP-IV degrades the incretins including Glucagon-like
peptide-2 (GLP-2). GLP-2 is known to help mucosal epithelial cell proliferation in the small intestine,
and thus inhibition of DPP-IV in the GIT may enhance epithelial re-growth in the small intestine [18].
DPP-IV inhibition is also known to alleviate the symptoms of hypertension and diabetes mellitus [19]
and also plays a role in regulation of satiety [20].
The lumen of the GIT is continually exposed to various pro-oxidants from the diet and the
environment, and is thus the site of a significant amount of oxidative reactions [21]. Natural
GEP-derived antioxidants could play a protective role against oxidative damage in the lumen.
Therefore, the present study not only investigated the in vitro potential of GEP as a source of bioactive
peptides with inhibitory activities against ACE-I, renin, DPP-IV and PAF-AH but also the antioxidant
potential of these peptides.
2. Results
2.1. Digestion of Proteins and Determination of Protein Content Using Sodium Dodecyl Sulphate
Polyacrylamide Gel Electrophoresis SDS-PAGE
LYS, MUC, SA, CA were subjected to simulated in vitro gastric and small intestinal digestion,
and TRYP was subjected to simulated in vitro small intestinal digestion alone. The protein content
of the gastric and small intestinal digests are given in Table 1. Tris-tricine sodium dodecyl sulphate
polyacrylamide gel electrophoresis (SDS-PAGE) analysis was used to confirm the digestion of selected
proteins (Figure 1). All of the proteins except LYS were digested extensively by the end of the simulated
small intestinal phase of digestion as shown in Figure 1 lanes 2, 3 and 4 for SA, lanes 2’, 3’ and 4’ for
MUC and lanes 5’ and 6’ for TRYP. Lanes 7’, 8’ and 9’ show the digestion of CA, which was used
as a control (a known dietary source of bioactive peptides). In the case of LYS (lanes 5, 6 and 7), a
significant amount of LYS («15 kDa band) remained intact even after sequential gastric and small
intestinal digestion.
2.2. Angiotensin-I Converting Enzyme (ACE-I) Inhibition by Digests and Enriched Fractions
The in vitro small intestinal digest of TRYP, and gastric and small intestinal digests of LYS,
MUC, SA and CA were found to inhibit ACE-I significantly (ě 97% inhibition); while the fractions
TRYP < 10-kDa, TRYP < 3-kDa, LYS < 10-kDa, LYS < 3-kDa, MUC < 10-kDa, MUC < 3-kDa, SA < 10-kDa,
SA < 3-kDa, CA < 10-kDa, CA < 3-kDa, inhibited ACE-I by 99% (˘1.00%), 99% (˘0.57%), 100%
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(˘0.01%), 98% (˘0.57%), 99% (˘1.15%), 100% (˘0.06%), 100% (˘0.57%), 100% (˘0.05%), 100% (˘0),
and 100% (˘0.58%), respectively at a concentration of 1 mg/mL (Figure 2). These values were found to
be comparable to the ACE-I inhibition values obtained for the positive control captopril (99% (˘0.57%))
which was also assayed at a concentration of 1 mg/mL. To ensure that the observed ACE-I inhibition
was due to the peptides present in the digested GEP fractions, rather than to the presence of the salts or
other potentially interfering digestion medium constituents, all samples were desalted using dialysis
as described previously. Dialyzed samples showed inhibition comparable to captopril when assayed
at 1 mg/mL.
Table 1. The protein content of the in vitro gastric (G) and small intestinal digests (G + SI) of the
gastrointestinal endogenous proteins, porcine trypsin (TRYP), human lysozyme (LYS), porcine salivary
mucin (MUC) and human serum albumin (SA), and dietary protein chicken albumin (CA).
Hydrolysate Protein Content (%)
TRYP G + SI 16.38
LYS G 97.89
LYS G + SI 98.48
MUC G 45.35
MUC G + SI 42.89
SA G 90.12
SA G + SI 87.71
CA G 85.56
CA G + SI 82.26
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Figure 1. Tris-tricine SDS-PAGE, of the in vitro gastric and small intestinal digests of the gastrointestinal
endogenous proteins, porcine trypsin (TRYP), human lysozyme (LYS), porcine salivary mucin (MUC)
and human serum albumin (SA), and dietary protein chicken albumin (CA) conducted under reducing
conditions. Each protein was analyzed prior to hydrolysis (U) and after gastric (G) and small intestinal
digestion (G + SI).
2.3. Renin Inhibition by Digests and Enriched Fractions
Among all the tested digests and fractions, the LYS < 3-kDa permeate fraction inhibited renin to the
greatest extent (40%˘1.79 inhibition) (Figure 3). The small intestinal enriched fractions TRYP < 10-kDa,
TRYP < 3-kDa, LYS < 10-kDa, MUC < 3-kDa, SA < 10-kDa, SA < 3-kDa, CA < 10-kDa and CA < 3-kDa
inhibited renin by 17% (˘1.19%), 9% (˘1.70%), 25% (˘1.76%), 13% (˘0.93%), 32% (˘1.51%), 24%
(˘1.64%), 13% (˘0.82%), and 14% (˘1.41%) respectively a a concentration of 1 mg/mL. TRYP SI,
MUC G, MUC G + SI, SA G, and CA G were found to inhibit renin by 16 (˘1.20%), 29% (˘.68%),
21% (˘2.39%), 18% (˘3.17%), and 13% (˘0.29%) respectively at a concentration of 1 mg/mL. From
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the gastric and small intestinal digests tested for renin inhibition LYS G, LYS G + SI, SA G + SI and
CA G + SI were found to have negligible renin inhibitory potential. The fraction MUC < 10-kDa also
showed no renin inhibition. The positive control (Z-Arg-Arg-Pro-Phe-His-Sta-Ile-His-Lys-(Boc)-Ome),
showed 100% (˘0.39%) inhibition when assayed at a concentration of 10 µM.Int. J. Mol. Sci. 2016, 17, 482 4 of 23 
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2.4. Renin, Platelet-Activating Factor-Acetylhydrolase (PAF-AH) Inhibition by Digests and  
Enriched Fractions 
LYS < 10-kDa was found to inhibit PAF-AH by up to 39% (±4.34%), while the fractions  
TRYP < 10-kDa, TRYP < 3-kDa, LYS < 3-kDa, SA < 10-kDa, SA < 3-kDa, CA < 10-kDa, CA < 3-kDa 
showed 20% (±9.93%), 19% (±6.25%), 21% (±6.9%), 18% (±1.99%), 33% (±5.69%), and 22% (±4.01%) and 
16% (±2.56%)) inhibition respectively at a concentration of 1 mg/mL (Figure 4). The fractions  
MUC < 10 and MUC < 3 showed no renin inhibition. TRYP SI, LYS G, LYS G + SI, SA G + SI, CA G 
and CA G + SI inhibited PAF-AH by 22% (±3.50%), 10% (±2.50%), 5% (±2.20%), 9% (±4.79%), 28% 
(±3.88%), and 30% (±0.81%) respectively at a concentration of 1 mg/mL. The digests MUC G, MUC  
Figure 2. Angiote sin I converting enzyme (AC - i ition by (A) gastric (G) and small intestinal
digests (G + SI) of the gastrointestinal endogenous proteins, porcine trypsin (TRYP), human lysozyme
(LYS), porcine salivary mucin (MUC) and human serum albumin (SA), and dietary protein chicken
albumin (CA); and (B) <10- and <3-kDa fractions of the small intestinal digests. All of the samples and
the positive control captopril were tested at the concentration of 1 mg/mL.
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2.4. Renin, Platelet-Activating Factor-Acetylhydrolase (PAF-AH) Inhibition by Digests and Enriched Fractions
LYS < 10-kDa was found to inhibit PAF-AH by up to 39% (˘4.34%), while the fractions
TRYP < 10-kDa, TRYP < 3-kDa, LYS < 3-kDa, SA < 10-kDa, SA < 3-kDa, CA < 10-kDa, CA < 3-kDa
showed 20% (˘9.93%), 19% (˘6.25%), 21% (˘6.9%), 18% (˘1.99%), 33% (˘5.69%), and 22% (˘4.01%)
and 16% (˘2.56%)) inhibition respectively at a concentration of 1 mg/mL (Figure 4). The fractions
MUC < 10 and MUC < 3 showed no renin inhibition. TRYP SI, LYS G, LYS G + SI, SA G + SI,
CA G and CA G + SI inhibited PAF-AH by 22% (˘3.50%), 10% (˘2.50%), 5% (˘2.20%), 9% (˘4.79%),
28% (˘3.88%), and 30% (˘0.81%) respectively at a concentration of 1 mg/mL. The digests MUC G,
MUC G + SI and SA G showed no renin inhibition. The positive control MAFP inhibited PAF-AH
by 70% (˘1.31%).
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A total of 19 and 91 peptides were identified in the <3-kDa fraction of the small intestinal digests 
of lysozyme and serum albumin respectively and 13 and 70 peptides were identified from the  
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Table 2. Gastrointestinal endogenous proteins (GEP)-derived peptide sequences found in the <3- and <10-kDa fractions of the in vitro small intestinal digests of
lysozyme and serum albumin. The samples were analyzed using electrospray ionization time of flight mass spectrometry (ESI-TOF MS).
Parent Protein and
Hydrolysate Fraction Peptide Amino acid Sequence
Protein
Fragment
Observed
Mass (Da)
Theoretical
Mass (Da)
Observed
m/z
Theoretical
m/z
Theoretical
Z
Lysozyme < 3-kDa fraction
ALLQDNIADAV f(101–111) 1141.60 1141.60 571.81 571.81 2
ALLQDNIADAVA f(101–112) 1212.64 1212.64 607.33 607.32 2
ARTLKRLGMDGYRGISL f(27–43) 1906.06 1906.06 477.52 477.52 4
DPQGIRAWV f(120–128) 1040.54 1040.54 521.28 521.28 2
GIFQINSRYW a f(73–82) 1298.66 1298.64 650.34 650.33 2
GMDGYRGISLANWM f(34–47) 1569.71 1569.71 785.86 785.86 2
LGMDGYRGISL f(33–43) 1180.59 1180.59 591.30 591.30 2
LGMDGYRGISLA f(33–44) 1251.63 1251.63 626.82 626.82 2
LLQDNIADAV b f(102–111) 1071.54 1071.54 536.78 536.78 2
NAGDRSTDYG f(64–73) 1054.43 1054.43 528.22 528.22 2
NAGDRSTDYGIFQ f(64–76) 1442.64 1442.64 722.33 722.33 2
NAGDRSTDYGIFQI f(64–77) 1555.73 1555.73 778.87 778.87 2
NAGDRSTDYGIFQIN f(64–78) 1669.77 1669.77 835.89 835.89 2
NYNAGDRSTD f(62–71) 1111.45 1111.45 556.73 556.73 2
NYNAGDRSTDYGIF f(62–75) 1591.69 1591.69 796.85 796.85 2
NYNAGDRSTDYGIFQ f(62–76) 1719.76 1719.75 860.89 860.88 2
NYNAGDRSTDYGIFQI f(62–77) 1832.84 1832.83 917.43 917.42 2
PQGIRAWVAW f(121–130) 1182.63 1182.63 592.32 592.32 2
YNAGDRSTDYGIF f(63–75) 1477.65 1477.65 739.83 739.83 2
Lysozyme < 10-kDa fraction
CNDGKTPGAV f(83–92) 960.43 960.43 481.22 481.22 2
CNDGKTPGAVNACHLSCS c,d f(83–100) 1773.73 1773.74 592.25 592.25 3
GIFQINSRYW f(73–82) 1282.65 1282.65 642.33 642.33 2
GMDGYRGISLANWM f(34–47) 1569.72 1569.71 785.87 785.86 2
NAGDRSTDYG f(64–73) 1054.43 1054.43 528.22 528.22 2
NAGDRSTDYGIFQI f(64–77) 1555.74 1555.73 778.88 778.87 2
NYNAGDRSTD f(62–71) 1111.45 1111.45 556.73 556.73 2
NYNAGDRSTDY f(62–72) 1274.52 1274.52 638.27 638.27 2
NYNAGDRSTDYG f(62–73) 1331.53 1331.54 666.77 666.78 2
NYNAGDRSTDYGIFQI f(62–77) 1832.85 1832.83 917.43 917.42 2
SALLQDNIADAV f(100–111) 1228.63 1228.63 615.32 615.32 2
YNAGDRSTDYG f(63–73) 1217.49 1217.49 609.75 609.75 2
ALLQDNIADAVACA e f(101–114) 1434.66 1434.67 718.34 718.34 2
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Table 2. Cont.
Parent Protein and
Hydrolysate Fraction Peptide Amino acid Sequence
Protein
Fragment
Observed
Mass (Da)
Theoretical
Mass (Da)
Observed
m/z
Theoretical
m/z
Theoretical
Z
Serum albumin < 3-kDa
fraction
AEAKDVFLGMFL f(344–355) 1339.69 1339.68 1339.69 670.85 2
AEFAEVSKLVTDL f(250–262) 1420.75 1420.74 1420.75 711.38 2
AEFAEVSKLVTDLT f f(250–263) 1549.79 1549.79 1549.79 775.90 2
AEFAEVSKLVTDLTK f(250–264) 1649.89 1649.89 1649.89 825.95 2
AEFAEVSKLVTDLTKVHT f(250–267) 1987.10 1987.06 1987.10 994.54 2
AEVENDEMPADLPSLA f(315–330) 1699.76 1699.76 1699.76 850.89 2
AEVSKLVTDLT f(253–63) 1174.64 1174.64 1174.64 588.33 2
AKVFDEFKPL f(395–404) 1192.65 1192.65 1192.65 597.33 2
AKVFDEFKPLVEEPQ f(395–409) 1774.91 1774.91 1774.91 888.46 2
ALEVDETYVPK f(514–524) 1262.64 1262.64 1262.64 632.33 2
ALEVDETYVPKE f(514–525) 1391.68 1391.68 1391.68 696.85 2
ALEVDETYVPKEF f(514–526) 1538.75 1538.75 1538.75 770.38 2
ALVLIAFA f(45–52) 816.51 816.51 816.51 409.26 2
ALVLIAFAQ f(45–53) 944.57 944.57 944.57 473.29 2
ALVLIAFAQY f(45–54) 1107.62 1107.63 1107.62 554.82 2
AVMDDFAAFVEK f(570–581) 1341.63 1341.63 1341.63 671.82 2
DDNPNLPR f(131–138) 939.44 939.44 939.44 470.73 2
DEFKPLVEEPQNLI f(399–412) 1669.86 1669.86 1669.86 835.94 2
DEFKPLVEEPQNLIK f(399–413) 1797.95 1797.95 1797.95 899.98 2
DETYVPKE f(518–525) 979.45 979.45 979.45 490.73 2
DLGEENFKALV f(37–47) 1233.63 1233.62 1233.63 617.82 2
DLGEENFKALVL f(37–48) 1346.71 1346.71 1346.71 674.36 2
DLPSLAADFVES f(325–336) 1262.60 1262.60 1262.60 632.31 2
DLPSLAADFVESK f(325–337) 1390.70 1390.70 1390.70 696.36 2
DVFLGMFLYE g f(348–357) 1248.77 1248.57 1248.77 625.29 2
EDHVKLVNEVTEFA f(61–74) 1628.81 1628.80 1628.81 815.41 2
ENDEMPADLPSL f(318–329) 1329.58 1329.58 1329.58 665.80 2
ENDEMPADLPSLAADFVES f(318–336) 2048.90 2048.89 2048.90 1025.45 2
ENDEMPADLPSLAADFVESK f(318–337) 2177.01 2176.98 2177.01 1089.50 2
EQLKAVMDD f(566–574) 1047.49 1047.49 1047.49 524.75 2
EQLKAVMDDF h f(566–575) 1176.55 1176.55 1176.55 589.28 2
EQLKAVMDDFA h f(566–576) 1247.59 1247.59 1247.59 624.80 2
EQLKAVMDDFAA h f(566–577) 1318.62 1318.62 1318.62 660.32 2
EVDETYVPK f(516–524) 1078.52 1078.52 1078.52 540.27 2
EVDETYVPKE f(516–525) 1207.57 1207.56 1207.57 604.79 2
EVDETYVPKEF f(516–526) 1354.63 1354.63 1354.63 678.32 2
EVDETYVPKEFN f(516–527) 1468.67 1468.67 1468.67 735.34 2
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Table 2. Cont.
Parent Protein and
Hydrolysate Fraction Peptide Amino acid Sequence
Protein
Fragment
Observed
Mass (Da)
Theoretical
Mass (Da)
Observed
m/z
Theoretical
m/z
Theoretical
Z
EVDETYVPKEFNAET i f(516–530) 1770.79 1770.78 1770.79 886.40 2
FDEFKPLVEEPQNLIK f(398–413) 1945.02 1945.02 1945.02 973.52 2
FKDLGEEN f(35–42) 950.44 950.43 950.44 476.22 2
FKDLGEENFKALV f(35–47) 1508.79 1508.79 1508.79 755.40 2
FKDLGEENFKALVL f(35–48) 1621.87 1621.87 1621.87 811.94 2
FPKAEFAEVSKLVTDLT f(247–263) 1894.01 1894.01 1894.01 632.34 3
FYAPELLFFAK f(173–183) 1344.71 1344.71 1344.71 673.36 2
KPLVEEPQN f(402–410) 1052.55 1052.55 1052.55 527.28 2
KPLVEEPQNLI f(402–412) 1278.72 1278.72 1278.72 640.37 2
KVPQVSTPT f(438–446) 955.53 955.53 955.53 478.77 2
KVPQVSTPTLV f(438–448) 1167.69 1167.69 1167.69 584.85 2
KVPQVSTPTLVEV f(438–450) 1395.79 1395.80 1395.79 698.91 2
KVPQVSTPTLVEVS f(438–451) 1482.83 1482.83 1482.83 742.42 2
LDELRDEG f(206–213) 945.44 945.44 945.44 473.73 2
LEVDETYVPK f(515–524) 1191.60 1191.60 1191.60 596.81 2
LEVDETYVPKE f(515–525) 1320.65 1320.64 1320.65 661.33 2
LQHKDDNPNLPR f(127–138) 1445.73 1445.74 1445.73 482.92 3
LVAASQAALG f(599–608) 899.51 899.51 899.51 450.76 2
LVNEVTEFA f(66–74) 1020.52 1020.51 1020.52 511.26 2
LVNEVTEFAK f(66–75) 1148.61 1148.61 1148.61 575.31 2
LVNEVTEFAKTCVADESAENCDK c,d f(66–88) 2512.11 2512.13 2512.11 629.04 4
LVRPEVDVM g f(139–147) 1072.56 1072.56 1072.56 537.29 2
NDEMPADLPSLA i f(318–330) 1272.56 1272.55 1272.56 637.28 2
NDEMPADLPSLAADF f(318–333) 1604.71 1604.70 1604.71 803.36 2
NDEMPADLPSLAADFVES f(318–336) 1919.86 1919.85 1919.86 960.93 2
NDEMPADLPSLAADFVESK f(318–337) 2047.95 2047.94 2047.95 1024.98 2
NEVTEFAKTCVADESAENCDK c,d f(68–88) 2299.96 2299.98 2299.96 1150.99 2
NRRPCFSALEVDETYVPKE d,j f(507–525) 2199.96 2200.09 2199.96 734.37 3
NYAEAKDVFLG f(342–352) 1225.60 1225.60 1225.60 613.81 2
NYAEAKDVFLGM f(342–353) 1356.64 1356.64 1356.64 679.33 2
NYAEAKDVFLGMFL f(342–355) 1616.83 1616.79 1616.83 809.40 2
QHKDDNPNLPR h f(128–138) 1315.62 1315.63 1315.62 439.55 3
QYLQQCPFEDHV d f(53–64) 1471.68 1471.67 1471.68 736.84 2
RETYGEM f(105–111) 884.37 884.37 884.37 443.19 2
RHPDYSVV f(361–368) 971.48 971.48 971.48 486.75 2
RHPDYSVVL f(361–369) 1084.57 1084.57 1084.57 543.29 2
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Table 2. Cont.
Parent Protein and
Hydrolysate Fraction Peptide Amino acid Sequence
Protein
Fragment
Observed
Mass (Da)
Theoretical
Mass (Da)
Observed
m/z
Theoretical
m/z
Theoretical
Z
SALEVDETYVPK f(513–524) 1349.67 1349.67 1349.67 675.84 2
SALEVDETYVPKE f(513–525) 1478.72 1478.71 1478.72 740.36 2
SALEVDETYVPKEF f(513–526) 1625.79 1625.78 1625.79 813.90 2
TPVSDRVT f(491–498) 873.45 873.46 873.45 437.74 2
VFDEFKP f(397–403) 880.43 880.43 880.43 441.22 2
VFDEFKPL f(397–404) 993.52 993.52 993.52 497.77 2
VFDEFKPLVEEPQ f(397–409) 1575.78 1575.78 1575.78 788.90 2
VFDEFKPLVEEPQN f(397–410) 1689.83 1689.82 1689.83 845.92 2
VFDEFKPLVEEPQNLI f(397–412) 1916.00 1915.99 1916.00 959.00 2
VKLVNEVTEFA f(64–74) 1247.68 1247.68 1247.68 624.85 2
VLIAFAQYL f(47–55) 1036.60 1036.60 1036.60 519.31 2
VPQVSTPTLVEVS f(439–451) 1354.74 1354.73 1354.74 678.37 2
VSTPTLVEVS f(442–451) 1030.56 1030.55 1030.56 516.28 2
DVFLGMFL g f(348–355) 956.47 956.47 956.47 479.24 2
TLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPR d,i f(103–138) 4216.84 4216.90 4216.84 844.39 5
LVNEVTEFAKTC d f(66–77) 1318.71 1318.68 1318.71 660.35 2
ENDEMPADLPSLA h f(318–330) 1382.60 1382.60 1382.60 692.31 2
LSVVLNQLCVL c f(477–87) 1231.69 1231.68 1231.69 616.85 2
Serum albumin < 10-kDa
fraction
AEAKDVFLGMF f(344–354) 1226.60 1226.60 614.31 614.31 2
AEAKDVFLGMFL f(344–355) 1339.70 1339.68 670.86 670.85 2
AEFAEVSKLVTDL f(250–262) 1420.76 1420.74 711.39 711.38 2
AEFAEVSKLVTDLT f(250–263) 1521.91 1521.79 761.96 761.90 2
AEFAEVSKLVTDLTK f(250–264) 1649.88 1649.89 550.97 550.97 3
AEVSKLVTDLT f(253–263) 1174.65 1174.64 588.33 588.33 2
AKVFDEFKPLVEEPQNLIK f(395–413) 2243.25 2243.22 748.76 748.75 3
ALVLIAFAQ f(45–53) 944.56 944.57 473.29 473.29 2
ALVLIAFAQY f(45–54) 1107.63 1107.63 554.82 554.82 2
APELLFFAK f(175–183) 1034.57 1034.58 518.29 518.30 2
AVMDDFAAFVE f(570–580) 1213.54 1213.53 607.78 607.77 2
AVMDDFAAFVEK f(570–581) 1341.64 1341.63 671.83 671.82 2
DEFKPLVEEPQNL f(399–411) 1556.80 1556.77 779.41 779.39 2
DEFKPLVEEPQNLI f(399–412) 1669.89 1669.86 835.95 835.94 2
DEFKPLVEEPQNLIK f(399–413) 1798.00 1797.95 900.01 899.98 2
DLGEENFKALVLI f(37–49) 1459.82 1459.79 730.92 730.90 2
DLGEENFKALVLIA f(37–50) 1530.85 1530.83 766.43 766.42 2
DLGEENFKALVLIAFAQ f(37–53) 1877.06 1876.99 939.54 939.50 2
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Table 2. Cont.
Parent Protein and
Hydrolysate Fraction Peptide Amino acid Sequence
Protein
Fragment
Observed
Mass (Da)
Theoretical
Mass (Da)
Observed
m/z
Theoretical
m/z
Theoretical
Z
DLPSLAADF f(325–333) 947.45 947.46 474.73 474.74 2
DLPSLAADFVES f(325–334) 1262.61 1262.60 632.31 632.31 2
DLPSLAADFVESK f(325–335) 1390.72 1390.70 696.37 696.36 2
DVFLGMFLY g f(348–366) 1119.53 1119.53 560.77 560.77 2
DVFLGMFLYE g f(348–367) 1248.57 1248.57 625.29 625.29 2
DVFLGMFLYEYA g f(348–369) 1482.70 1482.67 742.36 742.34 2
ENDEMPADLPSLA f(318–330) 1400.63 1400.61 701.32 701.31 2
EQLKAVMDDF f(566–575) 1176.55 1176.55 589.28 589.28 2
EQLKAVMDDFAA f(566–577) 1318.63 1318.62 660.32 660.32 2
EQLKAVMDDFAAF f(566–578) 1483.73 1483.70 742.87 742.86 2
EVDETYVPKE f(516–525) 1207.56 1207.56 604.79 604.79 2
FDEFKPLVEEPQNLIK f(398–413) 1945.04 1945.02 649.36 649.35 3
FKDLGEENFKALV f(35–47) 1508.81 1508.79 755.41 755.40 2
FKDLGEENFKALVL f(35–48) 1621.91 1621.87 811.96 811.94 2
FKDLGEENFKALVLI f(35–49) 1735.00 1734.96 868.51 868.49 2
FKDLGEENFKALVLIA f(35–50) 1806.04 1805.99 904.03 904.00 2
FKDLGEENFKALVLIAFAQ f(35–53) 2152.24 2152.16 1077.13 1077.09 2
FPKAEFAEVSKLVTDLT f(247–263) 1894.01 1894.01 632.35 632.34 3
FYAPELLFFA f(173–182) 1216.62 1216.62 609.32 609.32 2
FYAPELLFFAK f(173–183) 1344.73 1344.71 673.37 673.36 2
FYAPELLFFAKR f(173–184) 1500.79 1500.81 501.27 501.28 3
KDLGEENFKALVLIAFAQ f(36–53) 2005.11 2005.09 669.38 669.37 3
KVPQVSTPT f(438–446) 955.52 955.53 478.77 478.77 2
KVPQVSTPTLVEV f(438–450) 1395.81 1395.80 698.91 698.91 2
KVPQVSTPTLVEVS f(438–451) 1482.85 1482.83 742.43 742.42 2
KVPQVSTPTLVEVSRN k f(438–453) 1710.00 1709.92 856.01 855.97 2
LQHKDDNPNLPR f(127–138) 1445.71 1445.74 482.91 482.92 3
LVNEVTEFAKTCVADESAENCDKSLHTLF c,k f(66–94) 3210.60 3210.50 1071.21 1071.17 3
NDEMPADLPSLA f(319–330) 1271.58 1271.57 636.80 636.79 2
NDEMPADLPSLAADFVESK f(319–337) 2048.01 2047.94 1025.01 1024.98 2
NYAEAKDVFLGMF f(342–354) 1503.73 1503.71 752.87 752.86 2
NYAEAKDVFLGMFL g f(342–355) 1632.81 1632.79 817.41 817.40 2
RHPDYSVVLLL f(361–371) 1310.74 1310.73 656.38 656.37 2
SALEVDETYVPK f(513–524) 1349.68 1349.67 675.85 675.84 2
TKKVPQVSTPTLVEVSf f(436–451) 1739.99 1739.97 871.00 870.99 2
TYETTLEK f(376–383) 983.47 983.48 492.74 492.75 2
VFDEFKPL f(397–404) 993.50 993.52 497.76 497.77 2
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Table 2. Cont.
Parent Protein and
Hydrolysate Fraction Peptide Amino acid Sequence
Protein
Fragment
Observed
Mass (Da)
Theoretical
Mass (Da)
Observed
m/z
Theoretical
m/z
Theoretical
Z
VFDEFKPLVEEPQ f(397–409) 1575.81 1575.78 788.91 788.90 2
VFDEFKPLVEEPQN f(397–410) 1689.86 1689.82 845.94 845.92 2
VFDEFKPLVEEPQNL f(397–411) 1802.96 1802.91 902.49 902.46 2
VFDEFKPLVEEPQNLI f(397–412) 1916.05 1915.99 959.03 959.00 2
VFDEFKPLVEEPQNLIK f(397–413) 2044.11 2044.09 682.38 682.37 3
VFDEFKPLVEEPQNLIKQ f(397–414) 2172.21 2172.15 725.08 725.06 3
VLIAFAQYL f(47–55) 1036.58 1036.60 519.30 519.31 2
VPQVSTPTLVEV f(439–450) 1267.71 1267.70 634.86 634.86 2
VPQVSTPTLVEVS f(439–451) 1354.75 1354.73 678.38 678.37 2
EQLKAVMDDFA f(566–576) 1265.60 1265.60 633.81 633.81 2
YAPELLFFAK f(174–183) 1197.65 1197.64 599.83 599.83 2
LVRPEVDV f(139–146) 925.51 925.52 463.76 463.77 2
EVDETYVPK f(516–524) 1078.51 1078.52 540.26 540.27 2
LSQRFPKAEFAEVSKLVTDLT f(243–263) 2379.28 2378.28 595.83 595.58 4
VLIAFAQY f(47–54) 923.49 923.51 462.75 462.76 2
a Deamidated W; b Deamidated Q; c Dioxidation(C); d Cys– > Dha(C); e Trioxidation(C); f Formyl(K); g Oxidation(M); h Glu– > pyro-Glu@N-term; i Deamidated(N); j Dehydrated(S);
k Arg– > GluSA(R).
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3. Discussion
To date several studies have investigated the quantity of GEP found in the digestive contents of
animals [4,22,23] and humans [24–26], and the effect of dietary constituents such as protein (and its
structure), fiber and anti-nutritional factors on the GEP [27–30]. It is now widely accepted that GEP
contribute significantly to the amino acid pool in the GIT, and consequently are now recognized as
important in addition to estimation of the true amino acid requirements of humans [5,31]. However,
in spite of the knowledge that up to 80% of the GEP secreted into the gut lumen are digested and
reabsorbed by the end of the terminal ileum, the possibility that they may also give rise to bioactive
peptides has only recently been considered [1]. Quantitatively, in mammals, GEP are secreted in an
equal or greater amount as dietary proteins ingested per day [26]. However, while an extensive range
of dietary proteins have been investigated for their ability to generate bioactive peptides during food
processing, fermentation and gastrointestinal digestion in vivo, GEP have not been widely investigated.
Therefore, analogous to enzymatically-derived dietary bioactive peptides, peptides derived from GEP
in the gut lumen may also possess gut-specific bioactivities [2].
The present study used an in vitro digestion model to examine GEP as a source of peptides
with physiological effects including heart-health regulatory, GIT health beneficial, anti-inflammatory
and weight gain prevention. Four GEP and one dietary protein (chicken albumin) were selected to
examine their potential to generation bioactive peptides following simulated GIT digestion. This work
demonstrates that in vitro gastric and small intestinal digests of GEP possess biological activity relevant
to the GIT and overall human health. These biological activities include potential renin, ACE-I, DPP-IV
inhibitory and antioxidant activities.
GEP used in this work included TRYP, LYS, MUC, and SA. These were subjected to simulated,
sequential gastric and small intestinal digestion using pepsin and pancreatin (containing proteases
from the exocrine cells of the porcine pancreas), while TRYP was only subjected to small intestinal
digestion. Pepsin and proteolytic enzymes present in pancreatin digested all of the four GEP as shown
using SDS-PAGE (Figure 1), and the extent of digestion generally compared favorably to the protein
CA (Figure 1). LYS was not completely digested and this finding is in agreement with a previous study
that demonstrated that hen egg lysozyme, which is 57.5% homologous (BLAST identity match) to
human lysozyme [32], was only partially digested in the GIT [33].
All of the gastric and small intestinal digests, and the enriched fractions containing peptides
<10- and <3-kDa in size inhibited ACE-I when assayed at a concentration of 1 mg/mL and results
obtained were comparable to ACE-I inhibition values obtained for captopril and for food derived
ACE-I inhibitory peptides identified previously. To ensure that the observed ACE-I inhibition was
from the peptides in the tested GEP digests rather than the salts and chemical constituents of the
in vitro digestion medium, the samples were desalted by subjecting them to dialysis, and the dialyzed
samples also showed inhibition comparable to captopril (data not shown). In comparison, dietary
bioactive peptides, from various sources including cereals, legumes, meat, fish and poultry, have been
documented to show a wide range of ACE-I inhibition ranging from 1% to ě90% inhibition [34–36].
The ACE-I inhibition activity observed suggests that the enzyme may be inhibited by a broad-spectrum
of peptidic inhibitors. From a gut perspective, inhibition of ACE-I is important since it is now known
that an extensive RAAS exists within the GIT. While the GIT-RAAS is known to balance the fluid and
electrolyte dynamics in the gut, it is not entirely clear as to what the exact role of ACE-I inhibitors
may be in the context of the gut. It is important to note that, postprandial or functional hyperemia (an
increased blood flow to the gut after a meal (postprandial state)) is a known phenomenon that helps in
the digestion of food [37,38], and it may be that the dietary protein- and GEP-derived ACE-I inhibitory
peptides play a protective role against a severe rise in local hypertension in the GIT.
Only a few GEP digests including TRYP SI, MUC G, MUC G + SI, SA G and CA G inhibited renin.
While the LYS G + SI digest did not inhibit renin the fractions LYS <10-kDa and <3-kDa were found to
inhibit renin by 25% and 40% each, indicating that low molecular weight peptides derived from LYS
may be responsible for the observed inhibition. In comparison to previously reported values for renin
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and PAF-AH inhibition by peptides from dietary proteins, inhibition values obtained in the present
work were comparable. For example, a previous study investigated the renin inhibition of a papain
digest of the red seaweed Palmaria palmata and reported that a reverse phase high pressure liquid
chromatography (RP-HPLC) fraction of the latter hydrolysate inhibited renin by 58.97% (˘1.26%)
when assayed at a concentration of 1 mg/mL [39].
Although the small intestinal digest of LYS and SA inhibited PAF-AH by 5% and 9%, their
enriched fractions (LYS < 10-kDa and SA < 3-kDa) inhibited the PAF-AH by 39% and 33% respectively.
This suggests that smaller peptides derived from LYS and SA may be more effective inhibitors of
PAF-AH. The PAF-AH inhibitory values obtained in this work were comparable to those obtained
previously for a papain hydrolysate of Palmaria palmata which inhibited PAF-AH by 30.37% [40].
A similar trend was observed in the case of DPP-IV inhibition by GEP subjected to GI digestion.
While the gastric and small intestinal digests of all of the proteins showed either no inhibition or
low inhibition values (SA G and SA G + SI), following enrichment of the small intestinal digests a
substantial increase in the DPP-IV inhibitory activity was observed. For example, the SA < 3-kDa,
SA < 10-kDa, LYS < 10-kDa and LYS < 3-kDa were found to inhibit DPP-IV by greater than 35% at a
concentration of 1 mg/mL. In particular, the DPP-IV inhibition exerted by SA < 3-kDa (45% (˘1.24%)),
is comparable to the DPP-IV inhibition reported for the gastrointestinal digests of oat flour, alcalase
digest of oat glutelin and a tryptic digest of highland barley glutelin that were found to have IC50
values of 0.99, 0.13 and 1.83 mg/mL respectively [41]. In relation to gut health, the optimal inhibition of
DPP-IV may aid in remediation of non-steroidal anti-inflammatory drug-induced intestinal ulcers [42],
by possibly enhancing the beneficial amino acid- and bile acid-induced bicarbonate secretion in the
small intestine [43], besides promoting epithelial regrowth [18] and stimulating intestinal growth [44].
The extent of inhibition of the ACE-I, renin, DPP-IV and PAF-AH enzymes observed in the current
work is comparable to that of various food protein digests [40,45–47]. The inhibition of all of the
above mentioned enzymes by peptides is associated with a positive impact on cardiovascular health
and reduction of high blood pressure [19,48,49]. However, ACE-I, renin, DPP-IV and PAF-AH are
enzymes that are also present in the gut, and recent evidence suggests that inhibition of these enzymes
can impact positively on gut health and may help to prevent necrosis, ulcerative colitis and other
inflammatory disorders of the human gut [8,9,13,17].
Furthermore, the digested GEP and enriched fractions were also found to have considerable
antioxidant activity in vitro. Among the digests that were able to inhibit ABTS ion (TRYP SI, MUC
G, MUC G + SI, SA G + SI, and CA G + SI), SA G + SI had the highest total antioxidant capacity
value (137 µM¨TE/mg), which is much higher than the previously reported values (0.47 µM¨TE/mg
protein) for the 3-kDa fraction of in vitro digests of human milk [50]. However, the highest TAC-ABTS
values obtained for GEP in the present study are significantly lower than the values for human
plasma (430–569 µM¨TE) which was analyzed for TAC-ABTS using ABTS and hydrogen peroxide [51]
previously. In addition, a small increase in the ABTS scavenging was observed after fraction enrichment,
particularly for MUC protein. However, in the antioxidant potential measurement using the DPPH
radical assay, we found a greater difference between the un-fractionated GEP digest fractions and the
enriched fraction of the same GEP. For example, LYS G + SI inhibited DPPH by only 30% (˘1.84%) but
the <10-kDa fraction of the same sample inhibited DPPH by 54% (˘1.62), followed by the SA <3-kDa
that also inhibited DPPH by 49% (˘1.58%). The antioxidant activity of GEP-derived peptides may be
of great importance to gut health as an exclusive dependence on diet-derived antioxidants may not be
entirely possible given that our diet varies considerably [1]. The gut undergoes a significant turnover
of the epithelial lining and is constantly exposed to the external environment and various oxidants on
a daily basis, thus GEP may form an intrinsic source of potential antioxidant peptides that can offset
this regular damage.
In this work, the GEP serum albumin and lysozyme were found to inhibit enzymes in all of the
in vitro bioassays carried out and the results were comparable to enzyme inhibition values obtained
for the dietary protein chicken albumin (CA). In particular, the <10- and <3-kDa fractions of SA and
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LYS were found to be the most active. Consequently, the latter two fractions were examined further
using ESI-TOF MS to characterize the peptides present. Thirty-two peptides were identified in the
enriched fractions (10- and 3-kDa) of LYS, and 161 different peptides in the SA fractions. Most of the
identified peptides were within the general range of the chain length reported for bioactive peptides
(3–30 amino acids) [52,53], but tending towards the longer chain length (7–36 amino acids). Overall,
among all of the 22 amino acids, LYS has the highest amounts of the amino acids A (10.8%), R (10.8%)
and N (7.7%). In terms of the most commonly found amino acids in bioactive peptide sequences, LYS
sequences contained significant amounts of A (10.8%), R (10.8%), G (8.5%), L (6.2%), V (6.9%), Q (4.6%)
and Y (4.6%). In the <3 and <10 kDa fractions of LYS, the major amino acids observed were A, V, N, Q
and Y. Most of the peptide fractions identified were from the f(62–130) region of the protein, and a few
from the f(27–47) region of the protein. In particular, from the LYS fractions that showed the highest
DPPH inhibition, we have identified 10 peptide sequences that have an N residue at the N-terminal of
the peptide. These results are in agreement with the findings of Rajapakse, et al. [54], who identified
the two peptides NADFGLNGLEGLA and NGLEGLK, containing an N-terminal N residue. These
peptides, generated from squid, showed the greatest antioxidant effect in an in vitro analysis based on
lipid peroxidation studies previously. Overall, the SA protein derived peptides contained the highest
amounts (up to 10%) of the amino acids A, E, L, T and K. In terms of the most commonly found amino
acids in bioactive peptide sequences, SA was found to be rich in L (10.4%), V (7%), F (5.3%), T (4.8%),
P (4.1%) and R (4.1%). We observed the highest frequency of occurrence of peptides with D, E, K, F,
L, V, A, R, T and S in the peptides identified in the <3- and <10-kDa fraction of SA. Within the <3-
and <10-kDa fraction of SA, over 80 peptide fragments with a hydrophobic or aromatic amino acid
residues of A, V, L and F were identified, and the presence of these peptides is known to have a positive
impact on the renin inhibition [55] and antioxidant potential of peptides [56–58]. Thus, while both the
LYS and SA fractions were found to contain peptides with previously identified bioactive amino acids
such as A, L, V, R, T and F [54,59,60], the observed range of bioactivity in this study suggests that apart
from the constituting amino acids, the peptide structure and certain other amino acids may also play a
role in the bioactivity of various hydrolysates.
A majority of the peptides identified in the present study are novel sequences that have
not been reported from these GEP previously. However, we found two peptides in the
LYS < 3-kDa fractions (DPQGIRAWV (f(120–128)), and PQGIRAWVAW (f(121–130))) that are
subsequences [61] of a previously identified antimicrobial sequence reported from human lysozyme
DNIADAVACAKRVVRDPQGIRAWVAWRNR (f(87–115)) [35,62]. Future work will specifically aim to
chemically synthesize the identified peptides and examine their individual biological activities, which
will allow us to determine which particular GEP-derived peptide sequences result in ACE-I, renin,
DPP-IV, PAF-AH and antioxidant activity.
The present study, although limited in its scope, due to its in vitro nature, is the first to illustrate
that GEP are a source bioactive peptides with in vitro ACE-I, renin, PAF-AH and DPP-IV inhibitory
and antioxidant activities. The known amino acid composition of the peptides identified in the present
work may have contributed to the observed biological activities in vitro. However, the peptide structure
and certain lesser studied amino acids that were also found to be present in abundance may also
have positively contributed to the observed in vitro bioactivities. Indeed, some of the food derived
bioactive peptides with IC50 values in the range of 100 to 500 µM can be of nutritive/physiological
importance in that they can be active after oral administration [63]. It is known that peptides greater
than 4 amino acids in size are usually not absorbed into the blood. However, the bioavailability of the
peptides in this work should be further studied using in vitro transcytosis assays using cell models
with epithelial cell lines including the human epithelial cororectal adenocarcinoma cells (Caco-2) or
human brain microvascular endothelial cell lines (hCMEC/D3) as previously reported [64]. Further
in vivo work is essential to determine if GEP can indeed give rise to bioactive peptides during their
digestion in the gastrointestinal tract. However, the present study points towards the possibility that
the GEP may have the potential to constitute a feedback-like peptidergic system within the gut lumen,
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particularly considering that the GEP are constantly present in the gut and can be modulated by
dietary constituents.
4. Experimental Section
4.1. Materials and Reagents
Human recombinant LYS (P61626), human recombinant SA (P02768), porcine TRYP (P00761),
porcine MUC (Apomucin; (P12021)), CA (P01012), dimethyl sulfoxide, porcine salivary amylase,
porcine pepsin and porcine pancreatin, the antioxidant resveratrol and the ACE-I inhibitor captopril,
2,2-diphenyl-1-picrylhydrazyl (DPPH), and all of the tris-tricine SDS-PAGE reagents were supplied by
Sigma Aldrich (Dublin, Ireland). The ACE-I inhibition assay kit was supplied by Dojindo EU, GmbH
(Kumamoto, Japan), the 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) inhibition
based total antioxidant capacity assay kit was supplied by BioVision Inc. (Milpitas, CA, USA), the
ABTS total antioxidant capacity assay kit was supplied by Zen-Bio, Inc. (Research Triangle Park, NC,
USA) and the renin, PAF-AH and DPP-IV inhibition assay kits were all supplied by the Cayman
Chemical Company (Cambridge BioSciences, Cambridge, UK). The molecular weight cut-off filters
were obtained from Millipore (Tullagreen, Carrigtwohill, Cork city, Ireland). The 3.5 kDa dialysis
membrane was supplied by the medical supply company (Medical supply company (MSC), Dublin,
Ireland). All other chemicals used were of analytical grade (ě99% purity). Unless otherwise stated, all
reagents were made using Milli-Q deionized water.
4.2. Simulated Gastrointestinal Digestion of Selected Gastrointestinal Endogenous Proteins (GEP) and a Food
Protein Comparator
Four secreted endogenous gut proteins were selected for the present study, namely, porcine trypsin
(TRYP), human recombinant lysozyme (LYS), porcine salivary mucin (MUC) and serum albumin (SA).
Chicken albumin (CA) was included in the study for the purpose of comparison, as it is a known
source of food-derived bioactive peptides [65–68]. The molecular weights and the chain lengths of the
proteins examined in the present study are presented in Table 3.
Table 3. Gastrointestinal endogenous proteins (GEP) and dietary protein examined in the in vitro study.
Protein Chain Length Molecular Weight (Mw)(KDa)
Uniprot
Accession No.
Gut cryptome protein – – –
Trypsin (TRYP) 223 24 P00761
Lysozyme (LYS) 148 17 P61626
Porcine salivary mucin (Apomucin) (MUC) 1150 110 P12021
Serum albumin (SA) 609 69 P02768
Dietary protein – – –
Chicken albumin (CA) 385 43 P01012
All of the studied proteins were subjected to simulated static in vitro gastrointestinal digestion
using the INFOGEST method described previously [6]. Selected proteins were subjected to sequential
gastric and small intestinal digestions with the exception of TRYP. TRYP was subjected only to small
intestinal digestion as it enters the GIT lumen at the duodenum [69]. The simulated in vitro sequential
digestion was performed in triplicate. Samples (0.5 mL ˆ 3) of the hydrolysates of the chosen GEP at a
concentration of 0.5–0.0125 g/mL were collected after the gastric phase (G) and small intestinal phase
(G + SI) of digestion, freeze-dried and stored at ´30 ˝C until further analysis. The overall methodology
and major steps followed in the present study are shown in Figure 8. Furthermore, MWCO-based
ultra-filtration was applied to all of the small intestinal in vitro digests, to obtain <10- and <3-kDa sized
peptide-enriched fractions (labelled as TRYP/LYS/MUC/SA/CA <3- and <-10 kDa respectively). All
of the samples were desalted using a 3.5 kDa dialysis membrane.
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Figure 8. The in vitro experimental design and methodologies used to study the angiotensin I
converting enzyme (ACE-I), renin, Platelet-activating factor-acetylhydrolase (PAF-AH) and
dipeptidyl peptidase IV (DPP-IV) inhibition, and Total antioxidant capacity by 2,2’-azino-bis(3-
ethylbenzothiazoline-6-sulphonic acid) (ABTS) and 2,2-diphenyl-1-picrylhydrazyl (DPPH) inhibition
based antioxidant activity of the gastric and small intestinal hydrolysates and the small intestinal <10-
and <3-kDA fractions of gastrointestinal endogenous proteins porcine trypsin, porcine salivary mucin,
human recombinant lysozyme and serum albumin, and food protein chicken albumin. SDS-PAGE: Tris
tricine sodium dodecyl sulphate polyacrylamide gel electrophoresis; ESI-TOF MS/MS: Electrospray
ionization time of flight mass spectrometry.
4.3. Total Protein Analysis
The total protein content was determined using the Dumas method in accordance with the AOAC
method 992.15 (1990) and using a LECO FP628 Protein analyzer (LECO Corp., St. Joseph, MI, USA). A
conversion factor of 6.25 was used to estimate the protein content from the nitrogen content.
4.4. Tris Tricine Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) Analysis
Tris tricine SDS-PAGE peptide analysis was carried out using previously described methods [70,71].
GEP protein samples were diluted 1:10 with reducing PAGE sample buffer (2% or 4% SDS and 100 mM
dithiothreitol (DTT)) to obtain a concentration of 1 mg/mL. 5–10 µL of each diluted sample was loaded
onto a SDS-PAGE resolving gel (49.5% T, 3% C). The components of the resolving and stacking gels are
given in supplementary Table S1.
The loaded gel was run in a Bio-Rad Laboratories Miniprotean gel apparatus at a voltage of 100 V
for 2 h or until the dye front approached the bottom of the gel. Gels were stained using Coomassie
brillia t blue R250 (0.3%) for 1 h at 20 ˝C. Destaining was c rried out using 10% v/v acetic acid and
10% v/v 2-prop ol. Gels were destained for 48 h at 20 ˝C, with gentle shaking. Gels we e scanned
on a molecular Gel Doc XR system (Bio-Rad Laboratories, Berkeley, CA, USA) and the gel images
were analyzed using QuantityOne and ImageLab software programs (Bio-Rad Laboratories, Berkeley,
CA, USA).
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4.5. ACE-I Inhibition Assay
This assay was carried out using an ACE-I inhibitor assay kit in accordance with the
manufacturer’s instructions. All fractions were assayed at a concentration of 1 mg/mL sample
dissolved in HPLC grade water in triplicate. The known ACE-I inhibitor Captopril was used as a
positive control at a concentration of 1 mg/mL. ACE-I inhibition percentage values for each peptide
were calculated using the absorbance values obtained at 450 nm and the equation:
% ACE´ I inhibition “ pAbsorbance of Blank 1´Absorbance value of the
Inhibitorq{pAbsorbance of Blank 1´Blank 2qˆ 100
where, blank 1 is control without the addition of any inhibitor, blank 2 is the reagent blank, and the
inhibitor is the positive control or test sample (protein digest/peptide fraction).
4.6. Renin Inhibition Assay
The renin inhibition assay was carried out using a renin inhibitor screening kit in accordance with
the manufacturer’s instructions. Z-Arg-Arg-Pro-Phe-His-Sta-Ile-His-Lys-(Boc)-Ome (Sigma Aldrich,
Dublin, Ireland), a known renin inhibitor, was used as a positive control at a concentration of 10 µM. The
% inhibition of renin was calculated using the fluorescence values obtained and the following formula:
% renin inhibition “ p100% Initial activity values pAFq´fluorescence value
obtained for the test sampleq{100% initial activity pAFqˆ 100
where, test sample is protein digest/peptide fraction.
4.7. PAF-AH Inhibition Assay
This assay was performed using a PAF-AH inhibitor kit supplied by Cambridge BioSciences,
Cambridge, UK in accordance with the manufacturer’s instructions. All of the digests and enriched
fractions were assessed in triplicate. Methyl arachidonyl fluorophosphonate (MAFP), a known PAF-AH
inhibitor was used as a positive control at a concentration of 260 ng/mL.
4.8. DPP-IV Inhibition
The DPP-IV inhibitory activities of the digested protein samples were determined using a DPP-IV
inhibitor assay kit (Cambridge BioSciences, Cambridge, UK) in accordance with the manufacturer’s
instructions. Sitagliptin, a known DPP-IV inhibitor, was used as a positive control at a concentration of
100 µM. The percentage inhibition of DPP-IV was calculated as follows:
% Inhibition of DPP´ IV “ pRFU DPP´ IV activity´RFU Inhibitorq{pRFU DPP´IV activityqˆ 100
where, RFU DPP-IV activity is the fluorescence (measured in relative fluorescence units (RFU)) of the
measured without addition of any inhibitor, and RFU Inhibitor is the RFU measured in the presence of
the Sitagliptin or the test digests or enriched fractions.
4.9. 2,2’-Azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS)-Based Total Antioxidant Capacity
(ABTS-TAC) Assay
The assay was carried out using an ABTS antioxidant assay kit and performed as described by
the manufacturer. Trolox was used to obtain a standard curve and the assay buffer was used as a
blank. Resveratrol was used as a positive control. Antioxidant activity was calculated using the trolox
standard curve and expressed as µM trolox equivalents (TE).
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4.10. DPPH Inhibition
The DPPH inhibition assay was performed in accordance with previously described methods [72,73].
Briefly, triplicates of the digest or enriched fraction samples (1 mg/mL) and the positive control
(resveratrol) were prepared in the assay buffer. The samples and positive control solutions (285 µL)
were each combined with a freshly prepared methanolic DPPH solution in a Nunc™ 96-well
microWell™ plate to obtain a final DPPH concentration of 100 µM. The plate was incubated in dark at
room temperature for 30 min. The absorbance was then read at 515 nm. The control reaction mixture
contained DPPH and methanol without sample. The percentage DPPH inhibition was calculated using
the following equation:
% Inhibition DPPH “ pAbs Control´Abs Inhibitorq{Abs Controlˆ 100
where, Abs Control is the absorbance of the DPPH solution without any resveratrol or test peptides
and Abs Inhibitor is the absorbance of the test samples or positive control.
4.11. Electrospray Ionization Time of Flight Mass Spectrometry (ESI-TOF MS) Characterisation of Peptides
Present in the Most Active Fractions
The four fractions which showed the greatest extent of renin, DPP-IV, PAF-AH inhibition and
antioxidant activities were selected for peptide characterization. Briefly, the nano LC-MS/MS analysis
was performed using an Eksigent Nano-LC Ultra 1D Plus system (Eksigent of AB Sciex, Framingham,
CA, USA) coupled to the quadrupole-time-of-flight (Q-ToF) TripleTOF® 5600 system from AB Sciex
Instruments (Framingham, MA, USA) that was equipped with a nano-electrospray ionization source.
Lyophilized samples were re-suspended in 500 µL of H2O with 0.1% of TFA, and 20 µL of each
sample at different times of processing were cleaned and concentrated using Zip-Tip C18 with standard
bed format (Millipore Corporation, Bedford, MA, USA) according to manufacturer’s guidelines, and
kept at ´20 ˝C until analysis. Then, 5 µL of the supernatant was injected into the LC-MS/MS system.
After 5 min of pre-concentration, the trap column was automatically switched in-line onto a
nano-HPLC capillary column (3 µm, 75 µm ˆ 12.3 cm, C18) (Nikkyo Technos Co, Ltd., Tokyo, Japan).
Mobile phase A contained 0.1% v/v formic acid in water, and mobile phase B, contained 0.1% v/v
FA in 100% acetonitrile. A linear gradient from 5%–35% of solvent B over 90 min, and 10 min from
35%–65% of solvent B, at a flow rate of 0.3 µL/min and a column temperature of 30 ˝C was used. The
column outlet was directly coupled to a nano-electrospray ion (nESI) source. Operating conditions for
the Q/ToF mass spectrometer were positive polarity and information-dependent acquisition (IDA)
mode was used. A 0.25-s ToF MS scan from m/z of 100 to 1200 was performed, followed by 0.05-s
product ion scans from m/z of 100 to 1500 on the 50 most intense 1+ to 5+ charged ions. Automated
spectral processing, peak list generation, database search, and de novo sequencing for the identification
of peptides were performed using Mascot Distiller v2.4.2.0 software (Matrix Science, Inc., Boston,
MA, USA) (hppt://www.matrixscience.com). The UniProt protein database was used to identify the
peptides with a significance threshold p < 0.1 and a False Discovery Rate of 1.5%. The taxonomy used
for identification in the database was homo sapiens. The tolerance on the mass measurement was 0.3 Da
in MS mode and MS/MS ions.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/
17/4/482/s1.
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Abbreviations
ABTS 2,2’-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid)
ACE-I angiotensin-I Converting Enzyme
DPPH 2,2-diphenyl-1-picrylhydrazyl
DPP-IV dipeptidyl peptidase-IV
GEP Gastrointestinal endogenous proteins
GLP-2 Glucagon-like peptide-2
MAFP Methyl arachidonyl fluorophosphonate
MWCO Molecular weight cut-off
PAF-AH platelet-activating factor-acetylhydrolase
RAAS renin angiotensin aldosterone system
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis
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